PLAY PODCASTS
Frequently Asked Questions on Emerging Antibody–Drug Conjugates in the Treatment of Advanced Non-Small-Cell Lung Cancer
Episode 45

Frequently Asked Questions on Emerging Antibody–Drug Conjugates in the Treatment of Advanced Non-Small-Cell Lung Cancer

Listen to D. Ross Camidge, MD, PhD, and Joel W. Neal, MD, PhD, address questions from learners on investigational antibody–drug conjugates for advanced NSCLC.

Decera Clinical Education Oncology Podcast · Joel W. Neal MD PhD, Ross Camidge MD PhD

March 17, 20217m 40s

Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Show Notes

In this episode, D. Ross Camidge, MD, PhD, and Joel W. Neal, MD, PhD, answer questions on investigational antibody-drug conjugates for advanced NSCLC  

Presenters:

Ross Camidge, MD, PhD  
Professor of Medicine/Oncology  
University of Colorado Cancer Center
Aurora, Colorado

Joel W. Neal, MD, PhD  
Associate Professor of Medicine
Division of Oncology
Department of Medicine
Stanford University
Attending Physician
Stanford Cancer Institute
Palo Alto, California

Content based on an online IME program supported by educational grants from Daiichi Sankyo, Inc .

Link to full program:
http://bit.ly/3twpIyl

 


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Topics

ado-trastuzumab-emtansine t-dm1enapotamab vedotintelisotuzumab vedotinmirvetuximab soravtansinedestiny-lung01her2patritumab deruxtecansacituzumab govitecanceacam5 - sar408701lung cancertrastuzumab deruxtecan (t-dxd)anti-body drug conjugatejoel nealross camidgedatopotamab deruxtecan